Loading...
XWAR
PHR
Market cap11mUSD
Sep 22, Last price  
3.66PLN
1D
1.11%
1Q
4.90%
Jan 2017
-79.39%
IPO
-84.99%
Name

Pharmena SA

Chart & Performance

D1W1MN
P/E
—
P/S
152.11
EPS
—
Div Yield, %
23.35%
Shrs. gr., 5y
2.03%
Rev. gr., 5y
-52.51%
Revenues
268k
-97.28%
3,809,8466,379,5497,704,3868,778,3819,130,00014,138,00014,129,00017,473,00015,914,00012,511,00013,040,00011,099,0009,933,00015,213,00019,022,0009,837,000268,000
Net income
-1m
L
611,360771,541123,730608,997-4,100,000-2,843,000-4,086,000-3,616,000-1,664,000-2,389,000-444,000-9,573,000-6,958,000-4,639,000-1,616,00028,941,000-1,262,000
CFO
-3m
L
000666,906-4,054,000-3,836,000-5,751,000-4,175,000-950,000619,0003,613,000-13,146,000-2,243,000-3,225,0001,819,00033,032,000-2,531,000
Dividend
Apr 09, 20240.85 PLN/sh

Profile

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.
URL
https://www.pharmena.eu/
IPO date
Aug 25, 2008
Employees
24
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
268
-97.28%
9,837
-48.29%
19,022
25.04%
Cost of revenue
3,655
11,869
19,382
Unusual Expense (Income)
NOPBT
(3,387)
(2,032)
(360)
NOPBT Margin
Operating Taxes
(1,295)
5,908
204
Tax Rate
NOPAT
(2,092)
(7,940)
(564)
Net income
(1,262)
-104.36%
28,941
-1,890.90%
(1,616)
-65.16%
Dividends
(9,467)
Dividend yield
22.19%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
80
69
316
Long-term debt
408
295
704
Deferred revenue
Other long-term liabilities
27
21
2,207
Net debt
(1,257)
(21,873)
(45,027)
Cash flow
Cash from operating activities
(2,531)
33,032
1,819
CAPEX
(180)
(314)
(226)
Cash from investing activities
(8,358)
(3,132)
(219)
Cash from financing activities
(9,542)
(9,261)
(1,466)
FCF
(11,440)
(14,383)
3,342
Balance
Cash
1,745
22,237
1,592
Long term investments
44,455
Excess cash
1,732
21,745
45,096
Stockholders' equity
(142)
(21,951)
(49,909)
Invested Capital
12,833
44,381
45,660
ROIC
ROCE
8.47%
EV
Common stock shares outstanding
11,138
11,138
11,138
Price
3.83
-46.06%
7.10
26.79%
5.60
-29.20%
Market cap
42,658
-46.06%
79,078
26.79%
62,371
-29.03%
EV
41,401
56,910
17,042
EBITDA
(3,292)
(1,707)
201
EV/EBITDA
84.79
Interest
371
722
Interest/NOPBT